Viatris Looks Well-Positioned for Durable Growth From New Launches and Cost Savings Initiatives

Viatris is one of the largest generic drug manufacturers in the world. Generic drugs make up about 35% of the company's sales. Generics continue to suffer annual low- to mid-single-digit erosion in developed markets like North America and the majority of Europe. Because price and margin headwinds are predominantly in small-molecule oral tablets that are easy to produce, we expect Viatris’ pipeline to focus more on complex generics—drugs with complex formulations, dosage forms, or that are injected or have more complex administration.